Welcome to the ePoster Viewing Panel of INS-IM 2022

Go back

Title: Insights Into The Practice Of Neuromodulation Therapies (Excluding DBS) In India

e-poster Number: INSIM91

Category: Pain
Author Name: Dr Preeti Doshi
Institute: Jaslok Hospital and Research Centre
Co-Author Name: Dr Marc Russo, Dr Paresh Doshi
Abstract :
Introduction: There is a significant amount of discrepancy in the uptake of spinal cord stimulation therapies in Asian countries in comparison to the European and United States. These changes can be explained based on cultural bias and financial barriers. Method: An online questionnaire survey was sent out to the members of the national societies representing practitioners involved in neuromodulation in India. The responses were collected over time after sending various personal and email reminders. The validity of the collected data was cross verified by the implant data from the neuromodulation device distributors in India. Observations: As compared to the western countries, where the spinal cord stimulation (SCS) forms 70-90% of neuromodulation implants, only 10% of neuromodulation procedures include SCS in India. The development of Pain medicine has only accelerated in the last decade and hence it may take one more decade (based on the observations in United States) to reach the threshold point of turning around. Only handful of centres were found to be engaged in the use of advanced pain therapies, due to the lack of training. There are only very limited number of devices options available in India. The present armament area of devices is so restrictive that it cannot be applied to all indications. Similarly, we only have morphine to be administered for pain therapy through intrathecal drug delivery systems. Many other drugs like Ziconotide that is available in United States and Europe are not available in India. This further restrict the use and application of these Ziconotide that is available in United States and Europe are not available in India. This further restrict the use and application of these Ziconotide that is available in United States and Europe are not available in India. This further restrict the use and application of these